NY-ESO-1 protein formulated with immunostimulatory complexes (ISCOM (R) adjuvant) in patients with minimal residual disease induces a broad-based immune response involving CD4 & CD8 T lymphocytes and high titered antibody. Conference Paper uri icon

authors

  • Cebon, JS
  • Davis, ID
  • Chen, W
  • Parente, P
  • Jackson, H
  • Shackleton, M
  • Hopkins, W
  • Chen, QY
  • Murphy, R
  • Tai, TY
  • Dimopoulos, N
  • Scott, A
  • McArthur, G
  • Macgregor, D
  • Miloradovic, L
  • Green, S
  • Maraskovsky, E
  • Cuthbertson, A
  • Maher, D
  • Mitchell, S
  • Ritter, G
  • Stockert, E
  • Hoffman, EW
  • Pugliese, L
  • Old, LJ

publication date

  • December 1, 2003